Can’t agree more. He’s a rare breed. He has an unreal ability to...

Can’t agree more. He’s a rare breed. He has an unreal ability to garner trust from these medical institutions to license highly prized assets before any of the big boys get a sniff in, then an even better ability to head hunt leaders in the industry who have commercialised similar drugs before. And as you say what better place to carry out the trials than the institutions themselves who not only have skin in the game, but more than the money it’s their baby, their passion and their life goal to see it succeed for millions of patients. Look at Yuman Fong (IMU licensed COH) for example passionate, clever man who eat and breaths his craft.

Looking for a better word, everything CHM/IMU do is “clinical” as far as timing, strategy and execution. Announcements are a perfect balance of raising awareness of the company and professionalism.

Not worried about the share price, trading below cash now but which Bio isn’t apart from IMU who are further down the clinical path.. A chunk of tax selling going on which is adding to the s#%t storm macro, one would hate to be caught out when that sell side dries up again because with these high potential bio's they go up faster than they go down

As @Paulfool points out CHM-1101 cohort 3 data collection must be in full swing. also looking forward to CHM-2101 (CDH-17 out of U Penn) hitting the clinic those pre clinical models look very exciting.

As you have clearly done with both IMU and CHM. If you do the homework on the background all you have to do is let time and the professionals do the rest.. It's actually fascinating stuff to learn too.

GLTA